Cardiac dysfunction and metabolic inflexibility in a mouse model of diabetes without dyslipidemia

Diabetes

Volumn 67, Issue 6, 2018, Pages 1057-1067

  Rohm, Maria ^a   Savic, Dragana ^a   Ball, Vicky ^a   Curtis, M Kate ^a   Bonham, Sarah ^b   Fischer, Roman ^b   Legrave, Nathalie ^c   MacRae, James I ^c   Tyler, Damian J ^a   Ashcroft, Frances M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c THE FRANCIS CRICK INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; BRANCHED CHAIN AMINO ACID; GLIBENCLAMIDE; INSULIN; LACTIC ACID; MYRISTIC ACID; PALMITOLEIC ACID; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE KINASE 4; PYRUVIC ACID; TRICARBOXYLIC ACID; UNCOUPLING PROTEIN 3; ANTIDIABETIC AGENT; INWARDLY RECTIFYING POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FATTY ACID METABOLISM; GLUCOSE METABOLISM; HEART DISEASE; HEART MUSCLE METABOLISM; HEART OUTPUT; HEART STROKE VOLUME; HYPERGLYCEMIA; HYPOINSULINEMIA; IN VIVO STUDY; INSULIN BLOOD LEVEL; METABOLIC DISORDER; METABOLOMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; WESTERN BLOTTING; AMINO ACID SUBSTITUTION; ANIMAL; ANTIBODY SPECIFICITY; BLOOD; CARDIAC MUSCLE; COMPLICATION; DIABETIC CARDIOMYOPATHY; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG EFFECT; ENERGY METABOLISM; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HEART; HEART LEFT VENTRICLE FUNCTION; METABOLISM; MUTANT MOUSE STRAIN; MUTATION; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PROCEDURES; SECRETION (PROCESS); TRANSGENIC MOUSE;

AMINO ACID SUBSTITUTION; ANIMALS; CARDIAC OUTPUT; DIABETIC CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; ENERGY METABOLISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEART; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; METABOLOMICS; MICE, MUTANT STRAINS; MICE, TRANSGENIC; MUTATION; MYOCARDIUM; ORGAN SPECIFICITY; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PROTEOMICS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85047767414     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db17-1195     Document Type: Article

References (46)

1. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Fra-mingham study. Circulation 1979;59:8–13
2. Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia 2018;61:21–28
3. Scheuermann-Freestone M, Madsen PL, Manners D, et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 2003;107:3040–3046
4. Montaigne D, Marechal X, Coisne A, et al. Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. Circulation 2014;130:554–564
5. Anderson EJ, Kypson AP, Rodriguez E, Anderson CA, Lehr EJ, Neufer PD. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol 2009; 54:1891–1898
6. Isfort M, Stevens SC, Schaffer S, Jong CJ, Wold LE. Metabolic dysfunction in diabetic cardiomyopathy. Heart Fail Rev 2014;19:35–48
7. Abel ED, O’Shea KM, Ramasamy R. Insulin resistance: metabolic mechanisms and consequences in the heart. Arterioscler Thromb Vasc Biol 2012;32:2068–2076
8. Zlobine I, Gopal K, Ussher JR. Lipotoxicity in obesity and diabetes-related cardiac dysfunction. Biochim Biophys Acta 2016;1861:1555–1568
9. 13C Hyperpolarized Magnetic Resonance and Echocardiography Study. Diabetes 2015;64:2735–2743
10. Drosatos K, Schulze PC. Cardiac lipotoxicity: molecular pathways and therapeutic implications. Curr Heart Fail Rep 2013;10:109–121
11. Joubert M, Jagu B, Montaigne D, et al. The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model. Diabetes 2017;66:1030–1040
12. Teleb M, Popp Switzer M, Elhanafi S, Elfar A, San Juan ZT. Glycemic control and excess cardiovascular mortality in type 1 diabetes. Curr Cardiol Rep 2016;18:29
13. Aguilar-Bryan L, Bryan J. Neonatal diabetes mellitus. Endocr Rev 2008;29:265–291
14. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001;103:2668–2673
15. Brereton MF, Iberl M, Shimomura K, et al. Reversible changes in pancreatic islet structure and function produced by elevated blood glucose. Nat Commun 2014;5: 4639
16. Brereton MF, Rohm M, Shimomura K, et al. Hyperglycaemia induces metabolic dysfunction and glycogen accumulation in pancreatic b-cells. Nat Commun 2016;7: 13496
17. Schneider JE, Cassidy PJ, Lygate C, et al. Fast, high-resolution in vivo cine magnetic resonance imaging in normal and failing mouse hearts on a vertical 11.7 T system. J Magn Reson Imaging 2003;18:691–701
18. Haase A, Frahm J, Matthaei D, Hänicke W, Merboldt KD. FLASH imaging: rapid NMR imaging using low flip-angle pulses. 1986. J Magn Reson 2011;213:533–541
19. Ardenkjaer-Larsen JH, Fridlund B, Gram A, et al. Increase in signal-to-noise ratio of . 10,000 times in liquid-state NMR. Proc Natl Acad Sci U S A 2003;100:10158–10163
20. Dodd MS, Ball V, Bray R, et al. In vivo mouse cardiac hyperpolarized magnetic resonance spectroscopy. J Cardiovasc Magn Reson 2013;15:19
21. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 1997;129:35–43
22. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957;226:497–509
23. Lochmatter C, Fischer R, Charles PD, Yu Z, Powrie F, Kessler BM. Integrative phosphoproteomics links IL-23R signaling with metabolic adaptation in lymphocytes. Sci Rep 2016;6:24491
24. Behrends V, Tredwell GD, Bundy JG. A software complement to AMDIS for processing GC-MS metabolomic data. Anal Biochem 2011;415:206–208
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402–408
26. Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway. Circulation 2007; 115:909–917
27. Mitra R, Nogee DP, Zechner JF, et al. The transcriptional coactivators, PGC-1a and b, cooperate to maintain cardiac mitochondrial function during the early stages of insulin resistance. J Mol Cell Cardiol 2012;52:701–710
28. Finck BN, Lehman JJ, Leone TC, et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002;109:121–130
29. Kiilerich K, Adser H, Jakobsen AH, et al. PGC-1alpha increases PDH content but does not change acute PDH regulation in mouse skeletal muscle. Am J Physiol Regul Integr Comp Physiol 2010;299:R1350–R1359
30. Cole MA, Murray AJ, Cochlin LE, et al. A high fat diet increases mitochondrial fatty acid oxidation and uncoupling to decrease efficiency in rat heart. Basic Res Cardiol 2011;106:447–457
31. Crewe C, Kinter M, Szweda LI. Rapid inhibition of pyruvate dehydrogenase: an initiating event in high dietary fat-induced loss of metabolic flexibility in the heart. PLoS One 2013;8:e77280
32. Belke DD, Betuing S, Tuttle MJ, et al. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 2002;109:629–639
33. Shao D, Tian R. Glucose transporters in cardiac metabolism and hypertrophy. Compr Physiol 2015;6:331–351
34. Shi Q, Xu H, Yu H, et al. Inactivation and reactivation of the mitochondrial a-ketoglutarate dehydrogenase complex. J Biol Chem 2011;286:17640–17648
35. Faria A, Persaud SJ. Cardiac oxidative stress in diabetes: mechanisms and therapeutic potential. Pharmacol Ther 2017;172:50–62
36. Hecker M, Wagner AH. Role of protein carbonylation in diabetes. J Inherit Metab Dis 2018;41:29–38
37. Xu F, Tavintharan S, Sum CF, Woon K, Lim SC, Ong CN. Metabolic signature shift in type 2 diabetes mellitus revealed by mass spectrometry-based metabolomics. J Clin Endocrinol Metab 2013;98:E1060–E1065
38. Harper AE, Miller RH, Block KP. Branched-chain amino acid metabolism. Annu Rev Nutr 1984;4:409–454
39. Li T, Zhang Z, Kolwicz SC Jr, et al. Defective branched-chain amino acid catabolism disrupts glucose metabolism and sensitizes the heart to ischemia-reperfusion injury. Cell Metab 2017;25:374–385
40. Chatham JC, Forder JR. Relationship between cardiac function and substrate oxidation in hearts of diabetic rats. Am J Physiol 1997;273:H52–H58
41. Hall JL, Stanley WC, Lopaschuk GD, et al. Impaired pyruvate oxidation but normal glucose uptake in diabetic pig heart during dobutamine-induced work. Am J Physiol 1996;271:H2320–H2329
42. Seymour AM, Chatham JC. The effects of hypertrophy and diabetes on cardiac pyruvate dehydrogenase activity. J Mol Cell Cardiol 1997;29:2771–2778
43. Wu P, Sato J, Zhao Y, Jaskiewicz J, Popov KM, Harris RA. Starvation and diabetes increase the amount of pyruvate dehydrogenase kinase isoenzyme 4 in rat heart. Biochem J 1998;329:197–201
44. Huang B, Wu P, Bowker-Kinley MM, Harris RA. Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-alpha ligands, glucocorticoids, and insulin. Diabetes 2002;51:276–283
45. Schilling JD. The mitochondria in diabetic heart failure: from pathogenesis to therapeutic promise. Antioxid Redox Signal 2015;22:1515–1526
46. Yang J, Sambandam N, Han X, et al. CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res 2007;100:1208–1217